Oragenics (NYSE:OGEN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGENGet Rating) in a report published on Friday. The firm issued a hold rating on the stock.

Oragenics Stock Performance

Shares of NYSE:OGEN opened at $0.28 on Friday. The firm has a market cap of $32.89 million, a PE ratio of -2.03 and a beta of 0.07. The firm’s fifty day moving average is $0.35 and its 200-day moving average is $0.34. Oragenics has a 52 week low of $0.22 and a 52 week high of $0.77.

Oragenics (NYSE:OGENGet Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $0.03 million for the quarter.

About Oragenics

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

See Also

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.